• Contact Us
Pharmaceuticals & Life Sciences Blogs - VWV

Pharma & Life Sciences

Articles & Blogs Pharma & Life Sciences

More novel medicines drive faster global growth in next five years - IQVIA report

Thursday, 15 February 2024

Medicines use and global spending is going to be higher than previously thought in the five years to 2028, according to a report from IQVIA.

More novel medicines drive faster global growth in next five years - IQVIA report

Articles & Blogs Pharma & Life Sciences

A good companion for the long journey - companion diagnostics in the UK

Thursday, 15 February 2024

In the consultation concerning the reform of UK medical device regulation and the Government's published response to it, there are suggestions that the conspicuous absence of regulation and guidance on companion diagnostics will be fixed.

A good companion for the long journey - companion diagnostics in the UK

Articles & Blogs Pharma & Life Sciences

NHS extends Carbon Reduction Plan requirements from April 2024

Thursday, 15 February 2024

In October 2023, NHS England published important guidance on carbon reduction plans and net zero commitments in NHS procurements. NHS suppliers need to prepare for increasing attention on emissions reduction. It's not a 'nice to have'.

NHS extends Carbon Reduction Plan requirements from April 2024

Articles & Blogs Pharma & Life Sciences

New and updated UK clinical trial agreement templates published on IRAS

Monday, 22 January 2024

There is little room to negotiate the terms of these UK standard agreements, but sponsors should consider internal risk mitigation as part of the process.

New and updated UK clinical trial agreement templates published on IRAS

Articles & Blogs Pharma & Life Sciences

Generative AI in life sciences to create $100bn a year of opportunities - McKinsey

Monday, 22 January 2024

AI is the buzz theme right now. It can have a huge impact on the world. Pharma and life sciences fall within that. McKinsey has identified various opportunities for the sector.

Generative AI in life sciences to create $100bn a year of opportunities - McKinsey

Articles & Blogs Pharma & Life Sciences

Hope for Pharma in UK with new VPAG pricing scheme agreed

Thursday, 14 December 2023

The UK pricing scheme for pharma has been a major source of concern, mainly over the pricing mechanism and rebate scheme. This saw a rise in the rebate pharma has had to pay to 26.5% in 2023, but a new deal has now been announced.

Hope for Pharma in UK with new VPAG pricing scheme agreed

Articles & Blogs Pharma & Life Sciences

UK Government announces £100 Million fund for AI in life sciences and healthcare

Thursday, 14 December 2023

The UK Government has launched a new scheme to support the application of AI in life sciences and healthcare, with a £100 million fund to focus on areas where AI is hoped to make a difference in curing previously incurable diseases.

UK Government announces £100 Million fund for AI in life sciences and healthcare

Articles & Blogs Pharma & Life Sciences

AI generating copyright controversy

Thursday, 14 December 2023

One of the big questions concerning the use of AI relates to copyright. Both training and using an AI system might involve unlawful copying or publication of copyright works.

AI generating copyright controversy

Articles & Blogs Pharma & Life Sciences

Court decision shows benefits of negotiating to uphold liability clause

Thursday, 14 December 2023

A recent High Court decision has shown how a party may actually be better off by agreeing to negotiate its contracts.

Court decision shows benefits of negotiating to uphold liability clause

Articles & Blogs Pharma & Life Sciences

UK bodies team up to launch £30m fund to tackle anti-microbial resistance

Friday, 17 November 2023

Innovate UK, LifeArc and the Medicines Discovery Catapult have come together to create a £30m fund to seek to tackle antimicrobial resistance (AMR).

UK bodies team up to launch £30m fund to tackle anti-microbial resistance

Articles & Blogs Pharma & Life Sciences

The Bletchley Declaration - what does it mean for AI in Pharma?

Thursday, 16 November 2023

Artificial Intelligence (AI) is the buzz phrase of the year in the UK and beyond. After the UK held an AI Safety Summit in November, the countries participating signed up to the Bletchley Declaration. But what does it mean for pharma?

The Bletchley Declaration - what does it mean for AI in Pharma?

Articles & Blogs Pharma & Life Sciences

The start of the overhaul - low-risk UK clinical trial approvals made quicker

Thursday, 16 November 2023

The MHRA's guidance on clinical trial applications was updated in October. The guidance refers to a new notification scheme, which was the subject of an MHRA press release dated 12 October 2023.

The start of the overhaul - low-risk UK clinical trial approvals made quicker

Articles & Blogs Pharma & Life Sciences

Marketing authorisation - International Recognition Procedure confirmed

Thursday, 16 November 2023

From next year, organisations holding marketing authorisations (MA) in an approved list of countries can benefit from a new 'International Recognition Procedure' to gain access to the UK market.

Marketing authorisation - International Recognition Procedure confirmed

Articles & Blogs Pharma & Life Sciences

The future of expedited access to innovative medical devices - IDAP clearing the path for eight lucky applicants

Tuesday, 17 October 2023

How do medical devices get on the market quickly? There are lots of (usually long) answers to this question, but one significant new route will be via the Innovative Devices Access Pathway (IDAP).

The future of expedited access to innovative medical devices - IDAP clearing the path for eight lucky applicants

Articles & Blogs Pharma & Life Sciences

The lawyer's role in the future of UK clinical research - What would Lord O'Shaughnessy say?

Friday, 22 September 2023

Following last year's review from Lord O'Shaughnessy on the UK commercial clinical trial landscape, all of us (including lawyers) need to reflect on how to solve the issues flagged in the report.

The lawyer's role in the future of UK clinical research - What would Lord O'Shaughnessy say?